Compare Stocks

→ Automatic Income (from home) (From Awesomely, LLC) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.60	$46.84	$6.71 ▼ $64.72	$4.24B	0.97	4.47 million shs	1.92 million shs
SBTX Silverback Therapeutics	$9.75 +3.1%	$9.01	$2.80 ▼ $8.97	$351.57M	0.6	337,931 shs	364,184 shs
SPRY ARS Pharmaceuticals	$9.75 +3.1%	$9.02	$2.55 ▼ $11.27	$944.68M	0.88	536,209 shs	364,184 shs
URGN UroGen Pharma	$14.30 +0.3%	$15.30	$8.69 ▼ $24.13	$335.39M	1.09	297,767 shs	164,415 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	+0.06%	+69.51%	+133.30%	+824.18%
SBTX Silverback Therapeutics	+3.07%	+16.77%	+3.72%	+53.54%	+49.54%
SPRY ARS Pharmaceuticals	+3.07%	+16.77%	+3.72%	+53.54%	+47.73%
URGN UroGen Pharma	+0.28%	+1.06%	+4.69%	-13.18%	+11.72%

Investors Alert: The Next Big Thing in Weight Loss (Ad)

UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPN Alpine Immune Sciences	2.2346 of 5 stars	2.1	4.0	0.0	0.0	3.8	4.2	0.0
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	3.0789 of 5 stars	3.5	1.0	0.0	0.0	3.2	5.0	0.6
URGN UroGen Pharma	3.4647 of 5 stars	3.5	0.0	0.0	4.5	0.0	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	2.27	Hold	$50.33	-22.08% Downside
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	3.00	Buy	$18.50	89.74% Upside
URGN UroGen Pharma	3.00	Buy	$46.67	226.34% Upside

Current Analyst Ratings

Latest ALPN, SPRY, SBTX, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00
4/16/2024	ALPN Alpine Immune Sciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/12/2024	ALPN Alpine Immune Sciences	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$42.00 ➝ $65.00
4/11/2024	ALPN Alpine Immune Sciences	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/11/2024	ALPN Alpine Immune Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/11/2024	ALPN Alpine Immune Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral
4/11/2024	ALPN Alpine Immune Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$47.00 ➝ $65.00
4/11/2024	ALPN Alpine Immune Sciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$41.00 ➝ $65.00
4/11/2024	ALPN Alpine Immune Sciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
4/9/2024	ALPN Alpine Immune Sciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
4/4/2024	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$58.88M	71.93	N/A	N/A	$5.64 per share	11.45
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
SPRY ARS Pharmaceuticals	$30K	31,489.25	N/A	N/A	$2.40 per share	4.06
URGN UroGen Pharma	$82.71M	4.05	N/A	N/A	($2.78) per share	-5.14

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-54.66%	-15.54%	-11.34%	5/9/2024 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A
SPRY ARS Pharmaceuticals	-$54.37M	-$0.57	N/A	N/A	N/A	N/A	-22.24%	-21.50%	5/20/2024 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.73	N/A	N/A	N/A	-123.61%	N/A	-70.48%	5/13/2024 (Confirmed)

Latest ALPN, SPRY, SBTX, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2024	N/A	URGN UroGen Pharma	-$0.93	N/A	+$0.93	N/A	N/A	N/A
3/21/2024	Q4 2023	SPRY ARS Pharmaceuticals	-$0.14	-$0.07	+$0.07	-$0.07	N/A	N/A
3/18/2024	Q4 2023	ALPN Alpine Immune Sciences	-$0.32	$0.15	+$0.47	$0.15	$6.90 million	$30.85 million
3/14/2024	Q4 2023	URGN UroGen Pharma	-$0.67	-$0.72	-$0.05	-$0.72	$22.30 million	$23.53 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	7.86	7.86
SBTX Silverback Therapeutics	N/A	67.87	67.87
SPRY ARS Pharmaceuticals	N/A	96.92	96.92
URGN UroGen Pharma	N/A	5.42	5.24

Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
SBTX Silverback Therapeutics	74.89%
SPRY ARS Pharmaceuticals	68.16%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
SBTX Silverback Therapeutics	34.40%
SPRY ARS Pharmaceuticals	35.60%
URGN UroGen Pharma	11.13%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	65.56 million	37.83 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
SPRY ARS Pharmaceuticals	24	96.89 million	62.40 million	Optionable
URGN UroGen Pharma	198	23.45 million	20.84 million	Optionable

ALPN, SPRY, SBTX, and URGN Headlines

Source	Headline
	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 businesswire.com - May 4 at 3:20 PM
	New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial businesswire.com - May 4 at 11:50 AM
	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 businesswire.com - May 3 at 8:00 AM
	125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLC marketbeat.com - April 20 at 5:24 AM
	Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations markets.businessinsider.com - April 18 at 12:39 PM
	UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwright marketbeat.com - April 18 at 8:23 AM
	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers businesswire.com - April 17 at 12:02 PM
	UroGen's UGN-103 advances to Phase 3 for bladder cancer investing.com - April 16 at 10:43 PM
	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer businesswire.com - April 15 at 8:00 AM
	UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week finance.yahoo.com - April 14 at 1:17 PM
	Urogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Rating markets.businessinsider.com - April 4 at 3:29 PM
	UroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC Wainwright marketbeat.com - April 4 at 8:50 AM
	UroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stock insidertrades.com - March 22 at 6:30 AM
	UroGen: All Eyes On UGN-102 seekingalpha.com - March 18 at 11:48 PM
	UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line finance.yahoo.com - March 17 at 5:45 PM
	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 15 at 2:14 PM
	Analysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM) markets.businessinsider.com - March 14 at 11:32 PM
	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 finanznachrichten.de - March 14 at 6:32 PM
	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges finance.yahoo.com - March 14 at 1:26 PM
	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 investorplace.com - March 14 at 1:03 PM
	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates zacks.com - March 14 at 10:10 AM
	UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 finance.yahoo.com - March 14 at 8:25 AM
	UroGen Pharma earnings preview: what to expect markets.businessinsider.com - March 13 at 12:58 PM
	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) businesswire.com - March 8 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alpine Immune Sciences

NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Silverback Therapeutics

NASDAQ:SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

ARS Pharmaceuticals

NASDAQ:SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

UroGen Pharma

NASDAQ:URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial